Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Informal Caring Burden in HTA Series: Webinar 3 – Capturing carer burden in HTA: what is the future?
2 March 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Informal Caring Burden in HTA Series: Webinar 2 – How is carer burden captured in HTA, and what are some of the existing challenges?
27 February 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Informal Caring Burden in HTA Series: Webinar 1 – What is carer burden and why is it important in HTA?
22 February 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
The State of Play for Cost-effectiveness Thresholds
28 June 2022
In a new paper led by OHE, an international team of co-authors considers the evidence for supply-side cost-effectiveness thresholds, providing a set of recommendations for policymakers.…
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
As part of OHE’s presence at ISPOR 2022 in Washington DC, we hosted an issue panel tackling the hot topic of health technology assessment (HTA) of…
Sleepio: Lessons from the Frontier of Digital Therapeutics
31 May 2022
The National Institute for Health and Care Excellence (NICE) recently issued its first guidance for a digital therapeutic. NICE recommends the use of Sleepio for treating…